COMPOUNDS AFFECTING PIGMENT PRODUCTION AND METHODS FOR TREATMENT OF BACTERIAL DISEASES
Provided herein are compounds, derivatives thereof, composition comprising one or more of said compounds and derivatives, and methods for prevention and/or treatment of microbial infections and/or related diseases or conditions. The present compounds and/or derivatives thereof can be represented by Formula (II): The present methods include administering to a subject an effective amount of one or more compounds of Formula (II). In one embodiment, said microbial infections are bacterial infections. More specifically, said bacterial infections are staphylococcal infections.
1 . A composition comprising one or more compounds having Formula (II):
and prodrugs thereof,
wherein R1 is selected from:
wherein R3 and R4 are independently or jointly selected from a halogen or a halogen-containing moiety,
X is selected from N or C,
A is single bond or double bond, and
wherein R2 is selected from:
wherein R6 and R7 are independently or jointly selected from O or absent;
R8 and R9 are independently or jointly selected from the group consisting of heteroalkyl; aryl; heterocyclyl; cycloalkyl; cycloalkenyl; cycloalkynyl; and tetrahydroquinolinyl,
or R8 and R9 are optionally bonded together to form a four-, five-, or six-membered heterocyclyl, cycloalkenyl, or cycloalkyl, and
Z is selected from C or S.
2 . The composition of claim 1 , wherein the composition is administered to reduce a virulence of bacteria causing the microbial infections and/or related disease or conditions in said subject.
3 . The composition of claim 1 , wherein the composition further comprises one or more pharmaceutical acceptable carrier, salt, ester, excipient, vehicle, solvent, diluent, or any combination thereof.
4 . The composition of claim 1 , wherein the one or more compounds and/or prodrugs thereof are anti-virulent agents for bacteria.
5 . The composition of claim 4 , wherein the one or more compounds comprising:
and
6 . The composition of claim 1 , wherein the microbial infections and/or related diseases or conditions comprise infections of the skin and soft tissue, bone and joint, surgical wound, indwelling devices, lung and heart valves.
7 . The composition of claim 1 , wherein the microbial infections are bacterial infections.
8 . The composition of claim 7 , wherein the bacterial infections comprise Staphylococcus sp. Infections.
9 . The composition of claim 8 , wherein the Staphylococcus sp. Comprises Staphylococcus aureus or methicillin-resistant Staphylococcus aureus.
10 . The composition of claim 1 , wherein the composition inhibits biosynthesis of staphyloxanthin in the Staphylococcus aureus.
11 . The composition of claim 1 , wherein the composition blocks pigments production in Staphylococcus aureus.
12 . The composition of claim 1 , wherein said subject is a mammal.
13 . The composition of claim 1 , wherein said subject is human.
14 . The composition of claim 1 , wherein the composition is administered to the subject in need thereof through oral pathways in one or more forms comprising capsule, tablet, granule, spray, and/or syrup.
15 . The composition of claim 1 , wherein the composition increases sensitivity and/or susceptibility of microbes causing said microbial infections and/or related diseases or conditions to oxidation and neutrophil killing.
16 . The composition of claim 1 , wherein the halogen comprises F, Cl, Br and I.
17 . The composition of claim 16 , wherein the compound is represented by the following formula: